Recent News and Articles on the Keywords: heart + failure + congestive  Related to the article below (Last Update: 8/7/2008)

New Implant Device Remotely Monitors Heart Failure Patients at ... MarketWatch - Chest pain and shortness of breath are common symptoms that send tens of thousands of heart failure (HF) patients into US hospitals each month. ... COLUMN - New drug helps pets with congestive heart failure HollandSentinel.com, MI - Aug 5, 2008 By Eric Heitman We?ve had a newer drug available lately to help our patients who are in congestive heart failure. It is called Pimodendan. ... Livonia man gets device to help ailing heart its do job Detroit Free Press, United States - Aug 6, 2008 DuraHeart, made by Terumo Heart Inc. of Ann Arbor, hopes to provide more options for about 5 million Americans with congestive heart failure, a condition in ... First DuraHeart(TM) Left Ventricular Assist System Implanted in ... Earthtimes (press release) all 19 news articles »  TYO:4543 - PINK:TRUMF First US Patient to Receive New Heart-Assist Device Doing Well ... MarketWatch - Aug 5, 2008 Now, heart failure patients at UM and other centers across the US will have the opportunity to volunteer for a clinical trial of the DuraHeart, ... Livonia man gets new heart-assist device from Ann Arbor company Detroit Free Press, United States - Aug 5, 2008 DuraHeart, made by Terumo Heart, Inc, of Ann Arbor, hopes to provide more options for some 5 million Americans with congestive heart failure, a condition in ... Statistical Models and Patient Predictors of Readmission for Heart ... Cardiosource, DC - Study Question: Which statistical models are able to better predict readmissions for heart failure (HF)? Methods: The study investigators identified ... Body Mass Index and Mortality in Heart Failure: A Meta-Analysis Cardiosource, DC - Study Question: What is the relationship between increased body mass index (BMI) and mortality in patients with heart failure (HF)? ... Javno.hr Obesity seen protective in cases of heart failure Reuters - Aug 5, 2008 NEW YORK (Reuters Health) - Overweight and obese patients with heart failure seem to have a lower risk of dying than their normal-weight counterparts, ... Overweight problems seen even in infants Reuters UK all 13 news articles » Iron overload can lead to diabetes, heart failure The Plain Dealer - cleveland.com, OH - Aug 5, 2008 Over time, the toxic effects of the excess iron can lead to damaging diseases like diabetes, congestive heart failure, and endocrine system problems. ... New Study: Normal weight may be a sign of potential heart failure CaymanMama.com (press release), TX - Studies carried out on patients of a New York hospital reveal that most people who die of heart failure are people with normal weights. ...

A diuretic commonly prescribed to people with congestive heart failure can cause life-threatening complications if those patients are also on another drug that’s often used to treat the condition, Canadian researchers report.

The diuretic, spironolactone, can cause levels of potassium to rise to dangerous levels -- a condition called hyperkalemia -- in patients who take angiotensin-converting enzyme (ACE) inhibitors.

"After the publication of a major heart study that promoted the use of spironolactone, its prescribing rose" in Canada, explained lead researcher Dr. David Juurlink, a clinical pharmacologist at the University of Toronto.

Unfortunately, so did cases of hyperkalemia, added Juurlink, whose research appears in the Aug. 5 issue of the New England Journal of Medicine.

"There was a threefold increase in the hospitalization rates for high potassium across Ontario and a twofold increase in deaths involving high potassium," Juurlink said.

"When it came to the good side of this drug, we really didn’t see improvement in survival and heart failure improvement after the study was published," he added.

The Randomized Aldactone Evaluation Study (RALES), which was reported in 1999, claimed that spironolactone significantly improved survival for patients with severe congestive heart failure.

But the latest study revealed one complication: "The Randomized Aldactone Evaluation Study (RALES) demonstrated that spironolactone significantly improves outcomes in patients with severe heart failure. Use of angiotensin-converting enzyme (ACE) inhibitors is also indicated in these patients. However, life-threatening hyperkalemia can occur when these drugs are used together," Juurlink’s group wrote.

To arrive at that conclusion, his team collected data on hospital admissions for more than 1 million Ontario patients aged 66 and older from 1994 to 2001. All the patients were on ACE inhibitors.

They found the rate of spironolactone use increased about fivefold, from 34 per 1,000 patients in 1994 to 149 per 1,000 patients by late 2001. In addition, the number of people hospitalized for hyperkalemia increased from 2.5 per 1,000 patients in 1994 to 11 per 1,000 patients in 2001. The number of deaths also rose from about 0.3 per 1,000 patients in 1994 to 2.0 per 1,000 patients in 2001.

"We need to be more careful with this medication," Juurlink said. "This is a drug that is clearly good in the right patients with adequate monitoring. But in patients with other risk factors for elevations in their potassium, or patients we can’t monitor closely, we have to be more judicious in the use of the drug."

Potassium is essential for the proper functioning of the heart, kidneys, muscles, nerves and digestive system.

According to Juurlink, older patients, patients who have diabetes and those who have kidney problems are at greatest risk for developing hyperkalemia.

In addition to ACE inhibitors, heart failure patients often use potassium supplements, other diuretics and anti-inflammatory medications that can also increase potassium levels.

"Sometimes multiple factors can conspire in the same patient to really increase the risk of hyperkalemia. And that can have a very dangerous outcome," Juurlink said.

People shouldn’t stop their medication because of this problem, Juurlink said. "But if people are on spironolactone or are about to be put on spironolactone, they might want to ask their doctor if it’s really the right drug for them."

Dr. Ed Havranek, a professor of medicine at the University of Colorado, said, "This study tells us that medications that are thought to be safe and effective based on the results of clinical studies may not have the same safety and effectiveness when they enter the real world." "It points out the need for the U.S. to improve the capacity to monitor safety and effectiveness of medications after they reach the market, comparable to the capacity demonstrated in this Canadian study," he added.